Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1984-11-08
1987-11-10
Brown, J. R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514214, 514546, A61K 3170, A61K 3153, A61K 3122
Patent
active
047057793
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to synergistic pharmaceutical compositions of anti-pancreatic inflammatory effect, a process for preparing the same and a method for treating pancreatic inflammations.
In particular, the invention is directed to pharmaceutical compositions comprising one or more active ingredients of antiphlogistic and vascular effect, a process for preparing the same and a method for treating pancreatic inflammations with the said compositions.
BACKGROUND ART
In the last two decades the chronic inflammatory diseases of the pancreas appeared to cause increased clinical problems. This phenomenon is accompanied on one hand by the increased number of patients, on the other hand by the increased number of diagnostic methods. These facts are referred to in the following publication: Marks, J. N., Bank, S., Louw, I. H.: Leber, Magen, Darm. 6 257, 1976.
It is known in the art that the pancreatic inflammatory processes show specific features (Papp, M.: Congress of the Hungarian Gastroent. Society, Keszthely, Hungary, 1981).
The inflammation is of either ductalic or parenchimic feature, the deterioration of parenchyma, progressive histolysis, fibrotizing processes and cicatrization occur soon. The constant presence of the free digestive enzymes assuring the autoperpetuation is induced by the inflammatory mechanism, the oedematic processes and the trophic disorders to a high degree. Besides the inflammed oedema the compression of the subcapsular lymphatics also diminishes the microcirculation. G. Kaiser's and G. Hommel's observation is also of great importance. According to their report the decreasing demand for blood supply of the pancreas mass under deterioration induces adaptive intimafibrosis in the small blood-vessels. This process further reduces the blood amount rushing to the gland and it can be the basis of further atrophy, [Kaiser, G., Hommel, G.: Morphometrisch-statistische Analyse der Pankreasarterien bei chronischer Pankreatitis. Virchows Arch (Pathol. Anat.) 365 103 (1975)].
In spite of the above theoretical considerations there are no available pharmaceutical compositions of satisfactory effectiveness for the treatment of pancreatic inflammations until now. In order to relieve the patients of the unpleasant effect of the chronic inflammations the medical treatment is limited to administering an enzyme along with a particular diet. Such enzyme preparations are e.g. Dipankrine, Cotasym Forte or Panpur.
DISCLOSURE OF THE INVENTION
The aim of our research work was to develop a pharmaceutical composition which is suitable for the effective treatment of patients suffering from pancreatic inflammations. According to our observation from the group of antiinflammatory agents the steroids would rather induce recidiva while the prostaglandine antagonists are powerless.
Surprisingly we have found that the pharmaceutical compositions containing 3-dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-benzotria zine and at least one of the Vitamin P factors and/or (+)-2-(3,4-dihydroxyphenyl)-3,5,7-cromanetriole as active ingredients are effective against pancreatic inflammations.
As a factor of Vitamin P a water soluble rutine derivative, preferably 3',4',7-tris(.beta.-hydroxyethyl)-rutoside, can be used.
The weight ratio of 3-dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-benzotria zine and a factor of Vitamine P is between 2:1 to 1:1 in the compositions of the invention.
The weight ratio of 3-dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-benzotria zine and (+)-2-(3,4-dihydroxyphenyl)-3,5,7-cromanetriole varies within the range of 2:1 to 1:1 in the compositions of the invention.
The compositions according to the invention contain suitably 60 to 300 mg. of 3-dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-benzotria zine and altogether 60 to 300 mg. of a factor of Vitamin P and/or (+)-2-(3,4-dihydroxyphenyl)-3,5,7-cromanetriole per dosage unit.
The pharmaceutical compositions according to the invention contain optionally one
REFERENCES:
Merck Index, 10th Edition, Compound 9590 & 780.
Merck Index, II 759 & 1240, 9th Ed., 1974.
Bacsa Gyorgy
Bene nee Horvath Magdolna
Horvath nee Feher Eva
Jansco Sandor
Kiss nee Loss Ilona Maria
Biogal Gyogyszergyar of Debrecen and Alkaloida Vegyeszeti Gyar o
Brown J. R.
Dubno Herbert
Myers Jonathan
Rollins Jr. John W.
LandOfFree
Pharmaceutical compositions of anti-pancreatic inflammatory effe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions of anti-pancreatic inflammatory effe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions of anti-pancreatic inflammatory effe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1068173